Dementia Treatment Pipeline, Trial Access, and Research Evidence

Lecanemab and donanemab modestly slow early Alzheimer’s disease but are not cures; safety monitoring, eligibility, cost, and access remain important limitations. Roche’s Phase II trial of oral NLRP3 inhibitor RG6434 explores neuroinflammation, while efficacy is unknown; a small single-site rTMS study reported a preliminary signal requiring larger multisite validation.